Prokopenko O, Mirochnitchenko O. Ischemia-reperfusion-inducible protein modulates cell sensitivity to anticancer drugs by regulating activity of efflux transporter.
AMONG THE SEVERAL MECHANISMS MEDIATING cellular drug resistance, at least two major ones deal with transport activity, specifically, decreased uptake of water-soluble drugs and increased efflux of hydrophobic drugs from the cells (36) . Natural regulation of activity and acquired changes in gene expression of "polyspecific" transporters, including ATP-binding cassette (ABC) transporters, are currently under intensive investigation due to their ability to modulate sensitivity to drug therapy. Intracellular processing and trafficking of ABC transporters is a complex process regulated in part by their association with coat proteins (COPs). Participation of all three types of vesicles (clathrin-coated, COPI, and COPII-coated) has been reported for different stages of the transport, a variety of cells and conditions. Recently, significant attention has been devoted to COPI-mediated transport activity due to the discovery of the Arg-based retention signals, ability to mediate retrograde and anterograde traffic, and existence of different populations of COPI-coated vesicles (27, 28, 32) .
ABCB1 [P-glycoprotein (P-gp), ABCB subfamily], ABCC [multidrug resistance-associated proteins (MRPs)], and ABCG2 (ABCG subfamily) are examples of ABC proteins that confer drug resistance (20) . These transporters are expressed in normal tissues and involved in transport and tissue protection against xenobiotic toxicants, such as environmental carcinogens, metalloids, pesticides etc. They also have an important role in maintaining of the barrier function for several tissues, for example for blood-brain barrier. Recently, several laboratories reported tight control of the ABC transporters, especially P-glycoprotein in population of primitive stem cells, where they might have additional specific functions (7, 24) . These observations also indicate that targeting stem cell cancer cells might have additional challenges with respect to their efficient drug defense system (39) .
We recently reported the identification and characterization of a new mammalian protein, ischemia-reperfusion-inducible protein (IRIP), which belongs to the SUA5/YrdC/YciO protein family (13) . IRIP interacts with RS1, the product of the gene RSC1A1, which is involved in transcriptional and posttranscriptional regulation of a variety of cellular transporters, including sodium-D-glucose cotransporter sodium-dependent glucose cotransporter 1 (SGLT1) (42) . IRIP regulates endogenous as well as exogenously expressed uptake activity of the following transporters: human (h) organic cation transporter 2 (hOCT2), hOCT3, mouse (m) organic anion transporter (mOAT1), human neuronal dopamine transporter (hDAT), human norepinephrine transporter (hNET), and human 5-hydroxytryptamine (serotonin) transporter (hSERT) (13) . All of these transporters belong to the major facilitator superfamily according to the transport classification database and participate in transport of drugs and xenobiotics, some vitamins, and a variety of endogenous compounds such as choline and monoamine neurotransmitters. The IRIP regulatory mechanism remains to be determined. While searching for other transporters and important biological processes that may be regulated by IRIP, we investigated whether cell sensitivity to anticancer drugs can be modulated by the level of IRIP expression. In this study, we observed a significant correlation between the level of expression of hIRIP to cell resistance to a variety of the anticancer drugs, such as doxorubicin, etoposide, camptothecin, topotecan, and cisplatin. Importantly, despite the different mechanisms by which these drugs exert cellular toxicity, overexpression of wild-type hIRIP led to an increase in cell sensitivity to the drugs, whereas downregulation of expression by the introduction of the dominant-negative mutant led to increased resistance of the cells. We investigated the mechanism of the effect of hIRIP on doxorubicin toxicity and demonstrated that hIRIP regulates the efflux of doxorubicin from the cells. The P-gp transporter was investigated as one of hIRIP's targets. We observed that the level of hIRIP influences the processing and rate of the degradation of this transporter, as well as its stability on the cell surface. We hypothesize that one of the mechanisms of the hIRIP actions may be through the COPI-mediated transport pathways.
MATERIALS AND METHODS
Cell culture and transfection. HEK-293T cells and HeLa cell lines were grown at 37°C under a 5% CO 2 atmosphere in Dulbecco's modified Eagle's medium supplemented with 10% (vol/vol) bovine growth serum and containing penicillin/streptomycin. Culture medium for HeLa cell lines also contained Gx418 (450 g/ml). Stable HeLa-2 cell line was obtained by using pEF/myc/cyto plasmid (Invitrogen), HeLa-4 overexpress hIRIP, whereas HeLa-86 overexpress the T87L-K110I double-mutant dominant-negative myc-hIRIP (13) . Transient cell transfections were performed with Lipofectamine 2000 (Invitrogen) according to the manufacturer's protocol or by means of a Ca-phosphate precipitation technique (9) .
Cytotoxicity assay. HeLa-2, HeLa-4, and HeLa-86 cell lines were grown in 96-well plates to 80 -90% of confluence and were deprived of Gx418 48 h before the assay. Cytotoxic drugs (doxorubicin, etoposide, camptothecin, and cisplatin from Sigma; topotecan from LKT Laboratories) were added in 100 l of medium/well in the following concentrations: 0.025-10 M doxorubicin, 0.1-25 M etoposide, 0.1-50 M camptothecin, 0.1-10 M topotecan, and 2.5-50 M cisplatin. Cell viability was assessed using a neutral red assay (25) . Briefly, the cells were incubated for 1 h with 100 l/well of neutral red (50 g/ml) dissolved in supplemented culture medium, and the incorporated dye was extracted with 100 l of acetic acid/ ethanol/water (1:50:49), before recording the absorbance at 540 nm. Cell survival was expressed as a percentage, considering as 100% the value of parallel cultures incubated with only medium. Assays were performed with four replicate samples.
Doxorubicin uptake and efflux measurement. HeLa-2, HeLa-4, and HeLa-86 cell lines were grown in complete medium. Before each experiment, 3.5 ϫ 10 5 cells were transferred to suspension and doxorubicin was added in serum-free medium (final concentration 50 M). For uptake measurements, cells were incubated in the presence of the drug for different time periods. For efflux measurements, cells were incubated with doxorubicin for 2 h with mild rotation at 37°C. The influx was stopped by centrifugation and several washes with cold PBS. For efflux analysis, cells were resuspended in Dulbecco's modified Eagle's medium and incubated for 10, 20, 30, 40, and 60 min at 37°C. Cells then were placed on ice, centrifuged for 5 min, and washed two times with cold PBS. For analysis of the doxorubicin content, all cell pellets were resuspended in 1:1 mixture of ethanol and 0.3 N HCl. Aliquots of the suspension were used for measurement of the protein concentration. The remaining 100 l of the samples was checked for doxorubicin content using CytoFluor multiwell plate reader (series 4000, PerSeptive Biosystems) at 470-nm excitation and 585-nm emission. Cellular doxorubicin content was determined using a calibration curve and corrected for the protein content. Assay was performed with four replicate samples.
Plasmid constructs and point mutations. Expression plasmids pEF/ myc/cyto-hIRIP and pEF/myc/cyto-hIRIP double mutant (dm) were previously described (13) . The P-gp expression plasmid contains full-length P-gp cDNA (generous gift of Dr. M. Gottesman, National Institutes of Health, Bethesda, MD) flanked with Flag-Tag at the NH2 terminus and inserted via BamHI/XhoI sites into pcDNA3.1 (Invitrogen). P-gp K665A and R666A mutations were introduced using the QuikChange site-directed mutagenesis kit (Stratagene). Myc-tagged inactive GBF1/E794K mutant, hemagglutinin (HA)-tagged wild-type ADP-ribosylation factor 1 (ARF1), and HA-tagged constitutively active Arf1/Q71L mutant plasmids used to examine the role of the coat protein complex I (COPI) in P-gp trafficking were provided by Dr. E. Sztul (University of Alabama, Birmingham, AL) (32) .
Metabolic labeling and immunoprecipitation. HEK-293T cells in six-well plates at 24 h posttransfection were starved for 60 min with methionine and cysteine-free medium at 37°C to examine the biosynthesis profile of P-gp. The cells were then labeled with 100 mCi/ml of [ 35 S]methionine-cysteine Protein Labeling Mix (PerkinElmer) in methionine and cysteine-free medium at 37°C for various times (0.5, 1, and 2 h). To investigate P-gp processing, transfected cells after incubation in methionine and cysteine-free medium were pulse labeled in the presence of 100 mCi/ml of [
35 S]methionine-cysteine Protein Labeling Mix for 20 min and after three PBS washes were chased with normal growth medium for 1, 2, or 3 h. To study P-gp degradation, cells were labeled for 1 h and chased in the normal growth medium for 2, 4, 6, or 8 h. After finishing the incubation, cells were washed with PBS and lysed in a detergent solution (50 mM HEPES, pH 7.5, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100) containing protease inhibitor cocktail (Sigma). After brief sonication, lysates were centrifuged at 14,000 rpm for 20 min. To precipitate labeled P-gp protein, 20 l anti-Flag M2-Agarose (Sigma) were added and samples were incubated overnight at 4°C. Immunoprecipitates were washed four times in detergent solution, one time in PBS, and 20 l of 2ϫ Laemmli sample buffer were added. After 30 min of incubation at 37°C, samples were applied to the 7% SDS-PAGE, the gels were incubated in enhancer solution (EN 3 HANCER, NEN) for 1 h, dried, and exposed to X-ray film.
Surface biotinylation. HEK-293T cells were plated in six-well plates and transfected with 3.5 g of plasmid DNA. At 36 -48 h, plates were washed twice with cold PBS and incubated with 0.5 mg/ml EZ-link-sulfo-NHS-biotin (Pierce) in PBS with Mg/Ca (pH 8.0) at 4°C for 30 min with gentle agitation. Medium was changed for another portion of labeling mixture and incubated an additional 30 min. Cells were washed with PBS, and nonreacted biotin was quenched with 50 mM glycine in PBS for 20 min and washed twice with PBS. After that, cells for 0-h time point were lysed in RIPA buffer (50 mM Tris ⅐ HCl, pH 7.6, 150 mM NaCl, 1% Nonidet P-40, 0.5% sodium deoxycholate, 0.1% SDS, 1 mM dithiothreitol) with protease inhibitor cocktail (Sigma), whereas other sets of cells were incubated in DMEM with 10% bovine serum at 37°C for 60 and 120 min and then lysed in RIPA with inhibitors. Lysates were incubated for 20 min, passed several times through a syringe with 20-gauge needle, and centrifuged at 14,000 rpm for 20 min. Fifty microliters of Neutr-Avidin beads (Pierce) were then added, and samples were incubated overnight with gentle shaking. The precipitated proteins were washed five times with RIPA buffer and two times with PBS and denatured in 2ϫ Laemmli sample buffer at 65°C for 30 min. The precipitates were analyzed by 7% SDS-PAGE. After electrophoresis, gels were electroblotted onto polyvinylidene difluoride (PVDF) membrane and analyzed using anti-Flag M2 monoclonal antibody-peroxidase conjugate (Sigma). Blocking and antibody incubation solutions contained 5% nonfat dry milk. Proteins were detected using the Western Lighting chemiluminescence reagent (PerkinElmer Life Sciences). For quantitative analysis, bands on the films with linear exposure range were scanned on a model 300A densitometer using ImageQuant software (Amersham Biosciences).
Apoptosis and caspase assay. HeLa-2, HeLa-4, and HeLa-86 cell lines were grown in 24-well plates and incubated with the desired concentrations of doxorubicin or camptothecin. After 24 h, cells were trypsinized, washed once with PBS, and resuspended in 1ϫ binding buffer (10 mM HEPES, pH 7.4, 140 mM NaCl, 2.5 mM CaCl2) according to the Annexin V-FITC staining protocol (BD Biosciences). One-hundred microliters of cell suspension were combined with 5 l Annexin V-FITC (BD Biosciences) and 10 ml of propidium iodide (PI; 50 g/ml stock solution). After incubation for 15 min at room temperature, 400 l of 1ϫ binding Buffer was added to each tube and cells were analyzed by flow cytometry. Flow cytometry was carried out using 488-nm excitation and a 530-nm band-pass filter for fluorescein detection and 617-nm filter for PI detection. Data analysis was performed using CellQuest software (BD Biosciences). Caspase 3 and 8 activities in cells treated with doxorubicin and camptothecin were measured using Caspase-3 and 8 colorimetric assay kits (BioVision) according to the manufacturer's protocols.
Quantitative real-time PCR. Purification of total RNA from HeLa-2, HeLa-4, and HeLa-86 cell lines was performed using Absolutely RNA Miniprep kit (Stratagene). First-strand synthesis was conducted using TaqMan Reverse Transcription Reagents Kit (Applied Biosystems) using 0.4 g of total RNA and random hexamers. Quantitative real-time PCR was done with Power SYBR Green PCR Master Mix and an ABI 7900HT Real-Time PCR (Applied Biosys-tems). The following primers were used for transporters mRNA detection: ABCB1 (P-gp) (forward: 5Ј-GAGGAAGACATCACCA-GGTATGC-3Ј; reverse: 5Ј-GCCAGGCACCAAAATGAAACC-3Ј), ABCC1 (forward: 5Ј-CTCCTCCTATAGTGGGGACATCAG-3Ј; reverse: 5Ј-GTAGTCCCAGTACACGGAAAGC-3Ј), and ABCG2 (forward: 5Ј-TCAGCGGATACTACAGAGTGTCATC-3Ј; reverse: 5Ј-ATCTGCCTTTGGCTTCAATCCTAA-3Ј). The TATA-binding protein (TBP) transcript was used for normalization purposes (forward: 5Ј-TCAGCGGATACTACAGAGTGTCATC-3Ј; reverse: 5Ј-ATCT-GCCTTTGGCTTCAATCCTAA-3Ј). Reactions were performed in triplicate. Amplification specificity was confirmed by melting curve analysis and agarose gel electrophoresis. All real-time quantitative PCR data were captured and analyzed using SDS software (version 2.2; Applied Biosystems). The ratio of the relative concentration of the target molecule to TBP was calculated.
Immunoprecipitation and Western blot analysis.
To analyze the level of ubiquitination, transfected HEK-293T cells after 48 h were nontreated or treated with 5 M MG132 (Sigma). After 24 h of treatment, cells were rinsed with ice-cold PBS and lysed in detergent solution (50 mM HEPES, pH 7.5, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100) with protease inhibitors and 10 mM N-ethylmaleimide (Sigma). The samples were homogenized by brief sonication and then centrifuged at 12,000 g for 20 min. Equal amounts of the cell lysate were incubated with anti-Flag M2-Agarose overnight at 4°C. The precipitate was washed five times with lysis buffer and two times with PBS. Proteins were eluted by addition of 2ϫ SDS sample buffer and incubation for 20 min at 37°C. Eluted proteins were separated by 7% SDS-PAGE, transferred to the PVDF membrane and detected by anti-ubiquitin primary antibody (Ab) (P4D1, Cell Signaling) and anti-mouse horseradish peroxidase (HRP)-conjugated IgG (Cell Signaling) as a secondary Ab using Western Lighting chemiluminescence reagent (PerkinElmer Life Sciences). For COP-␣ and P-gp interaction studies, HEK-293T cells were transfected with pcDNA3.1 or Flagtagged P-gp expression plasmid and after 48 h washed and lysed as described above. Lysates were precleaned by incubation with Protein A/G PLUS-Agarose (Santa Cruz Biotechnology) for 1 h and immunoprecipitated by anti-Flag M2-Agarose or anti-COP-␣ goat polyclonal Ab and then with Protein A/G PLUS-Agarose (both from Santa Cruz Biotechnology) overnight. Anti-COP-␣ goat polyclonal Ab for one of the samples was preincubated with COP-␣ peptide (GeneTex) as a negative control. The precipitate was washed five times with lysis buffer and two times with PBS. Proteins were eluted by addition of the 2ϫ SDS sample buffer and incubation for 20 min at 37°C. Eluted proteins were analyzed by SDS-PAGE and Western blotting with anti-COP-␣ goat polyclonal Ab and then rabbit anti-goat HRPconjugated IgG (Santa Cruz Biotechnology) or with anti-Flag HRPconjugated Ab (Sigma).
Statistical analysis. All values are given as means Ϯ SE, unless indicated otherwise. A two-tailed unpaired Student's t-test was used to assess the significance of differences between two sets of data. For all analyses, P Ͻ 0.05 was considered statistically significant.
RESULTS

IRIP modulates cell sensitivity to cytotoxic anticancer drugs.
HeLa cell lines overexpressing hIRIP or dominant-negative hIRIP mutant were used to assess the effect of IRIP on cytotoxic activity of several anticancer drugs. We tested anticancer drugs with different mechanisms of toxicity: doxorubicin, etoposide, cisplatin, camptothecin, and the water-soluble camptothecin analog, topotecan. Cells were treated with different concentrations of these drugs, and cell viability was followed using a neutral red assay. As shown in Fig. 1 , overexpression of wild-type hIRIP sensitized cells to all chemicals used for investigation, whereas downregulation of hIRIP by overexpression of the double mutant led to the significant increase of the cell resistance. Doxorubicin and camptothecin have been shown to cause cell death by inducing apoptosis as well as necrosis in a concentration-and time-dependent manner. HeLa-2, HeLa-4, and HeLa-86 cell lines were treated with different concentrations of doxorubicin (0.5 and 2.5 M) and camptothecin (2.5 and 10 M) for 24 h. A dose-dependent increase in apoptotic and necrotic/dead cells was observed by annexin V and PI staining in HeLa-2 and HeLa-4 cells, with HeLa-4 showing higher sensitivity to both drugs (see Table 1 ) at 24 h. In contrast, HeLa-86 cells at these concentrations of the doxorubicin and camptothecin at 24 h did not reveal presence of any significant apoptotic/ necrotic cell populations. The induction of apoptosis-specific pathways was also assessed by measuring caspase 3 and caspase 8 activities using chromogenic substrates. As it is shown in Fig. 2 , A and B, both caspases were activated after doxorubicin and camptothecin treatment in HeLa-2 and HeLa-4 cells. In both cases the level of the activation was higher in HeLa-4 cells than in HeLa-2 cells. Activation of caspase 3 and 8 was also detected in HeLa-86 cells at 2.5 M and at both 2.5 and 10 M doxorubicin, respectively, but it was significantly lower than the level of the corresponding enzyme activity in two other tested cell lines. Data obtained correlate well with the results of the cytotoxicity experiments and support the ability of IRIP to increase sensitivity of the stable cell line to the several anticancer cytotoxic drugs, whereas downregulation of its activity enhanced cell resistance.
IRIP inhibits doxorubicin efflux. Anticancer drugs use a variety of mechanisms for cellular uptake: from passive diffusion to active transport (31) . Since both cellular uptake and efflux can be a target of IRIP activity due to its ability to modulate activity of a variety of transporters (13) , further studies were focused on doxorubicin, which in free form travels through the cell membrane predominantly by passive diffusion. We decided to investigate whether IRIP can modulate the doxorubicin accumulation as well as its efflux from the cells. Cell lines with different level of IRIP and dmIRIP expression were exposed to doxorubicin, and intracellular accumulation of the drug was measured by fluorimetry in the lysates. Data indicated that there were no differences in the accumulation of the drug between cell lines (data not shown). We investigated the release of doxorubicin in time-dependent manner. As shown in Fig. 3A , HeLa 4 cells released doxorubicin at a significantly slower rate than control HeLa-2 cells, whereas HeLa-86 cells released the drug faster than control cells or HeLa-4 cells. Differences in the intracellular concentration of the doxorubicin in these cell lines correlated with its cytotoxicity (see Fig. 1 ).
P-glycoprotein drug efflux transporter as a target of IRIP. Data presented in the previous section clearly show significant difference in the rates of the efflux of the doxorubicin between our model cell lines cells. Modulation of the energy-dependent efflux of anticancer drugs via ABC transporters is one of the most common mechanisms of development of drug resistance by cancer cells. Therefore, it was investigated whether trans-porters of this family were affected by hIRIP expression. We began by measuring the level of expression of the several known doxorubicin resistance-conferring members belonging to the human ABC family: ABCB1 (P-gp, ABCB subfamily), ABCC (MRPs), and ABCG2 (ABCG subfamily) (36) . Total RNA was purified from HeLa-2, HeLa-4, and HeLa-86 cell lines and was subjected to reverse transcription and quantitative real-time PCR. As shown in Fig. 3B , levels of all three transporters were very similar in these cell lines. We cannot exclude the possibility that hIRIP may influence the expression levels of other relevant transporters. It is also important to take into account our previous data about inability of IRIP to influence the total level of expression of other transporters, which nevertheless are targets of its regulation (13) . Thus, effects of hIRIP on the efflux transporters are likely to be posttranscriptional as in the case of OCT and monoamine transporters. To establish a model system to test whether cellular resistance to doxorubicin mediated by exogenous P-gp can be modulated by hIRIP, HeLa-2 and HeLa-4 cell lines were transiently transfected with P-gp expression plasmid and cell viability was examined following drug exposure. Results presented in Fig. 4 indicate that overexpression of P-gp increased the resistance of HeLa-2 cells to doxorubicin toxicity. This effect was eliminated in the HeLa-4 cell line by overexpression of hIRIP, suggesting that P-gp may be one of the targets of this protein.
IRIP does not influence P-gp biosynthesis but affects its processing and promotes degradation.
It is well established that transporters undergo very complex regulation in normal and disease conditions, including control of protein synthesis, posttranslational modifications, assembly, oligomerization, cell surface delivery, and endocytic retrieval/recycling. Results of the experiments in previous sections as well as measurements of the level of expression of endogenous and transiently expressed P-gp by Western blot analysis (data not shown) indicate that hIRIP does not affect overall P-gp mRNA and protein synthesis. To examine other possible mechanisms of the regulation by hIRIP, rates of P-gp biosynthesis, processing, and degradation have been measured by 35 S-labeling and immunoprecipitation of P-gp in HEK-293T cells cotransfected by P-gp encoding plasmid with pEF/myc/cyto, pEF/myc/cyto-hIRIP, or pEF/myc/cyto-hIRIPdm. Pulse-labeling experiment (see Fig. 5 , A and D) demonstrated a gradual increase in the presence of the labeled P-gp immunoprecipitated from whole cell lysates. No significant differences in the rate or total amount of labeled transporter have been observed at different time points in the presence of the excess hIRIP or its dominant-negative mutant. To investigate P-gp processing, transfected cells were pulse labeled for a short period of time and then incubated in normal complete medium. Newly synthesized P-gp usually migrates at ϳ150 kDa due to the N-linked oligosaccharide chains, but during the transport through the Golgi apparatus, N-linked oligosaccharides undergo processing and the mature form of P-gp thus migrates at ϳ170 kDa (22) . As shown in Fig. 5B , based on the pulse-chase assay, processing of wild-type P-gp (band b) to the mature form (band a) occurred more rapidly in the presence of excess of hIRIPdm and more slowly in the presence of the hIRIP compared with cotransfection with vector alone. The graph showing the representative ratio of the "a" form to the total amount of the protein is presented in Fig.  5E . To examine the effects of hIRIP on the degradation of P-gp, cellular proteins were labeled for 1 h and the rate of the degradation was followed for 2, 4, 6, and 8 h. P-gp in the presence of hIRIPdm showed the lowest rate of degradation, followed by that in the presence of the vector. The fastest rate of degradation was observed upon overexpression of wild-type hIRIP (Fig. 5, C and F) . To test whether decreased stability of P-gp leads to the destabilization of the transporter on the cell surface, we labeled P-gp on the cell surface by EZ-link-sulfo-NHS-biotin (Pierce) and followed its disappearance in chase experiment. As seen from Fig. 6, A and B , overexpression of hIRIP significantly affected the stability of P-gp on the surface of the cells. Cotransfection with the dominant-negative hIRIP mutant resulted in prolonged presence of the intact protein.
Taken together, these data suggest that hIRIP may influence P-gp maturation and degradation rates, whereas biosynthesis of the transporter is not affected.
IRIP and P-gp ubiquitination. To investigate whether the level of ubiquitination of the P-gp is affected by hIRIP in HEK-293T cells, the cells were cotransfected with P-gp expressing plasmid and pEF/myc/cyto, pEF/myc/cyto-hIRIP, or pEF/ myc/cyto-hIRIPdm. After 24 h, cells were exposed to proteasome inhibitor MG132 (5 M). Control cells were not treated with the inhibitor. The cells were immunoprecipitated using anti-ubiquitin antibodies after 24 h. Precipitated proteins were then analyzed using Western blot analysis with antibodies against Flag-Tag. If P-gp is targeted to the proteasome upon ubiquitination, treatment with inhibitor should lead to the accumulation of the ubiquitinated form of the P-gp. Treatment with MG132 induced P-gp modification that appeared as a high-molecular-weight "smearing" (see Fig. 6C ). Most importantly, more intense signals were observed in cells transfected with vector and hIRIP and less intense signals were observed in cells transfected with hIRIP mutant. No difference was observed between cells transfected by vector and wild-type hIRIP, which might be due to the sufficient quantity of endogenous hIRIP in HEK-293T cells mediating maximum level of possible ubiquitination at these conditions or not sufficient level of resolution achieved by Western blot analysis. Data obtained suggested that increased P-gp degradation rates in the presence of high hIRIP level are due to the increased ubiquitinmediated protein degradation in proteasomes.
Arg-based motif and P-gp trafficking. Arg-based signals have been implicated in the quality control as well as regulation of surface expression, supporting the complex role of COPI in intracellular trafficking (26) . Comparison of the primary amino acid sequences of the human P-gp and its homologues from other species revealed rather conserved Arg-based sequence at the intercellular loop of the protein (Fig. 7A) . Importantly, combinatorial screening has shown that clusters of Arg act as particular strong localization signals in mammalian cells if preceded by hydrophobic amino acid (46) . In the case of P-gp, a cluster of Arg was preceded by conserved Leu-Ile signal. In several species including humans, one of the Arg is replaced with Lys. Combination of both amino acids in Arg-based signals has been reported as well (26) . To test whether processing of the P-gp will be affected by mutation of the predicted Arg-based signal, we mutated the IRKR sequence to IRAA and after transient transfection of HEK-293T cells, pulse labeled cells with 35 S and followed P-gp processing for 1, 2, 3, and 6 h. As shown in Fig. 7B , almost all wild-type P-gp was detected in mature form at 3 h, whereas P-gp mutant contained a significant portion of the 150-kDa form even after 6 h. These results indicate that P-gp is most likely a cargo for transport via Arg-based signal.
IRIP influences the association of P-gp with COP-␣. To test whether COPI can interact with P-gp directly, immunoprecipitation studies were performed using Flag-tagged P-gp. HEK-293T cells were transfected with a P-gp expressing plasmid, and lysates were immunoprecipitated with anti-COP-␣ or antiFlag antibodies, resolved on PAGE, and filters were probed with anti-Flag or anti-COP-␣ antibodies, respectively, after Western blotting. As shown in Fig. 8, A and B, specific interaction of P-p with endogenous COP-␣ in HEK-293T cells was observed. Then we tested whether this interaction is affected by the level of hIRIP expression. For this purpose, cells were cotransfected with P-gp expressing plasmid and pEF/myc/ cyto, pEF/myc/cyto-hIRIP, or pEF/myc/cyto-hIRIPdm. After 48 h, lysates immunoprecipitated with anti-COP-␣ antibodies and immunoprecipitates with corresponding controls were analyzed by Western blotting using anti-Flag antibodies. As seen from Fig. 8C , the quantity of COP-␣ interacting with P-gp increased in the cells overexpressing hIRIP and significantly decreased in the presence of dominant-negative hIRIP mutant in comparison to the cells transfected with P-gp expressing plasmid and vector alone. The level of expression of P-gp was almost identical in all transfected cells (Fig. 8C, top gel) . To further confirm the involvement of COPI complex in P-gp trafficking, we introduced a dominant-negative mutant protein that alters COPI dynamics and investigated its effect on sensitivity of transiently transfected cells to doxorubicin. Wildtype ARF, inactive mutant of the ARF guanine nucleotide exchange factor GBF1 (GBF1/E794K), and GTP-restricted mutant of ARF (ARF1/Q71L) coding plasmids and pcDNA4.0/ TO/myc-his (Invitrogen) as a vector control (32) were cotransfected with P-gp. It was shown by others that introduction of ARF and GBF1 mutants interferes with proper COPI function (32) . Results of the HEK-293T survival experiments are shown in Fig. 9 . Cotransfection of P-gp with mutant proteins led to decreased cell survival at both doxorubicin concentrations eliminating P-gp-mediated resistance. No significant effect was observed upon introduction of wild-type ARF. These data further confirmed the important role of COPI in P-gp function.
DISCUSSION
Cell sensitivity to anticancer agents is one of the key principles of the anticancer chemotherapy. Most of the anticancer drugs act intracellularly, and maximally achieved concentrations actually determine their toxicity. Therefore investigation of the regulatory mechanisms for the intracellular and efflux transport of these drugs is of primary importance. We previously reported that activities of exogenous organic cation transporters (OCT2 and OCT3), organic anion transporter (OAT1), and monoamine transporters were inhibited by IRIP (13), a new human protein, which belongs to the SUA5/YrdC/ YciO protein family. We report here that this protein can modulate cell sensitivity to several anticancer drugs by affecting transporters activity. According to our results, hIRIP is able to regulate the activity of one of the ABC transporters, P-gp or MDR1 transporter.
We tested cells overexpressing wild-type hIRIP and dominant-negative hIRIP mutant for sensitivity to a variety of anticancer drugs having different mechanisms of toxicity, including topoisomerase I and II inhibitors and DNA intercalating agents. In all cases we observed potentiation of the cell sensitivity to the drugs in the presence of increased level of hIRIP and significant increase in cell resistance upon introduction of dominant-negative hIRIP mutant. Some of the drugs, such as doxorubicin, enter the cells by a passive diffusion, whereas others, like cisplatin, camptothecin, and topotecan, are transported by combination of active and passive mechanisms (10, 31, 34) . A variety of transporters are involved in the efflux of these drugs; for example, several members of the ATP- Fig. 7 . Identification of arginine-based sorting motif in P-gp. A: amino acid sequence alignment of P-gp fragment from different species. Conserved hypothetical arginine-based trafficking signal is underlined. B: processing of wild-type P-gp and mutant P-gp, in which arginine-based signal was removed by mutagenesis. To investigate the effect of mutations on P-gp processing, cells were transfected with P-gp and P-gp mutant encoding plasmids, incubated in methionine and cysteine-free medium, pulse labeled with [
35 S]methioninecysteine labeling mix for 20 min, and chased in normal growth medium for 1, 2, or 3 h. Labeled cells were lysed and immunoprecipitated with anti-Flag Ab-conjugated beads. Immunoprecipitated proteins were separated by electrophoresis, and dried gels were subjected to autoradiography. The positions of the mature (a) and core-glycosylated forms (b) of the P-gp are indicated. Fig. 6 . hIRIP overexpression destabilizes P-gp on the cell surface, whereas overexpression of the dominant-negative hIRIP mutant increased its stability. A: human embryonic kidney (HEK)-293T cells were cotransfected with P-gp expression plasmid and vector (pEF/myc/cyto), wild-type hIRIP (pEF/myc/ cyto-hIRIP), or mutant hIRIP dm (pEF/myc/cyto-hIRIPdm) expression plasmids and biotinylated for 1 h at 4°C. After cell surface biotinylation, cells were incubated in the cell culture medium at 37°C for the time period indicated. binding family of drug efflux proteins are implicated in resistance to camptothecins, including P-gp (4), MRP1 (5), MRP2 (17) , and breast cancer resistance protein (30) . Because of the possible influence of hIRIP on both types of the transporters, influx as well as efflux, the net effect on the toxicity of the several drugs can be mixed. For example, IRIP had only a limited effect on cisplatin cytotoxicity in our experiments (see Fig. 1 ). It was established that one of the key uptake transporter for cisplatin is OCT2 (8) , which as we previously reported is inhibited by hIRIP (13) . Several transporters implicated previously in cisplatin efflux, including ABCC2 (MRP2, canalicular multispecific organic anion transporter) (11) and two members of the multidrug and toxin extrusion family (multidrug and toxin extrusion protein subfamilies MATE1 and MATE2-K) (44) , potentially can also be affected by hIRIP. Therefore, at least some of the transporters mediating influx as well as efflux of the cisplatin most likely are affected by hIRIP activity and that leads to the overall marginal effect. Doxorubicin toxicity was analyzed as a relatively simple system due to the influx of the drug into the cell by diffusion, and our data suggest that this efflux is modulated by hIRIP.
We measured the level of expression of several ABC family transporters known to participate in doxorubicin efflux from the cells and conclude that the level of expression of hIRIP does not affect the level of mRNA expression of the transporters.
It is well known that ABC transporters undergo a complex secretory and endosomal pathway by sequential packaging into vesicular carriers that deliver proteins from one intracellular compartment to another. The labeling experiments show that hIRIP does not affect the rate of the transporter synthesis but influences its maturation and cell-surface stability. It also was recently reported that trafficking pathways used by a particular transporter can be cell specific; for example, trafficking of cystic fibrosis transmembrane conductance regulator (CFTR) can be COPI dependent in nonepithelial cells, such as HeLa and HEK-293, which are being used in our experiments, or it can be COPI independent (45) . Also, processing of the transporter in transfected cells is less efficient than that of the Fig. 9 . Effect of dominant-negative mutant proteins that alter coat protein complex I (COPI) dynamics on sensitivity of transfected with P-gp HEK-293T cells to doxorubicin. HEK-293T cells were cotransfected with vector (pEF/ myc/cyto), P-gp, and either Myc-tagged GBF1/E794K inactive mutant that causes COPI dissociation from membranes, wild-type ADP-ribosylation factor 1 (ARF1), or the Arf1/Q71L mutant that stabilizes COPI on membranes. After 24 h, cells were treated with doxorubicin (5 and 20 M), and after another 24 h of incubation, cell survival was measured by neutral red assay. Expression of mutant GBF1 or ARF inhibited doxorubicin resistance mediated by the transfected P-gp. Results of three independent experiments are presented as means Ϯ SE. *P Ͻ 0.05 in comparison to the measurements conducted in samples from the cells transfected with the vector plasmid. Whole cell extracts were immunoprecipitated with anti-Flag Ab, anti-COP-␣ Ab, or nonspecific Ab (NS). The presence of the P-gp and COP-␣ was detected by Western blot analysis with anti-Flag (A) or anti-COP-␣ (B) Ab. Samples labeled "total lysates" were used as controls and were not immunoprecipitated. Sample COP-␣ Ab contained COP-␣ peptide for neutralized control. Positions of the proteins are shown by arrowheads. To investigate the effect of IRIP on the interaction of P-gp with COP-␣, cotransfection experiments were conducted (C). HEK-293T cells were cotransfected with P-gp expression plasmid and vector (pEF/myc/cyto), wild-type hIRIP (pEF/myc/cyto-hIRIP), or mutant hIRIP (pEF/myc/cyto-hIRIPdm) expression plasmids as indicated. Total lysates were tested by Western blotting on the presence of the P-gp (top) and immunoprecipitated with anti-COP-␣ Ab or nonspecific Ab (NS) (bottom). Immunoprecipitates were analyzed by Western blotting with anti-Flag Ab. As it is shown on the autoradiogram, overexpression of the hIRIP leads to the increase of association of the P-gp and endogenous COP-␣, whereas overexpression of the dominant-negative hIRIP mutant resulted in the decrease of this complex.
endogenously expressed protein (40) . An important role for clathrin-adaptin-dependent mechanisms in the endocytic traffic of P-gp (at least in intestinal carcinoma LS174T cells) has been also suggested (16) .
Increased rate of the degradation of total protein as well as P-gp on the surface of the cellular membrane in the presence of the excess hIRIP led us to investigate whether ubiquitinproteasomal pathway is involved in the process. Stability and function of the P-gp as well as other members of the ABC family can be regulated by this pathway (15, 18, 43, 47) . Using proteasome inhibitor, we were able to demonstrate that the level of ubiquitination and rate of P-gp degradation are modulated by the level of hIRIP expression.
Because of the effect of hIRIP on P-gp processing, we analyzed possible sorting pathways that might be a target of this protein. Intra-Golgi transport mechanisms rely heavily on COPI vesicles mediating anterograde and retrograde cargo movement. The important role of COPI in trafficking of the CFTR, which is structurally similar to P-gp, has been reported (32, 45) . Several sorting motifs were identified in membrane proteins, (such as KKXX or RXR motifs) regulating proper protein maturation. Several studies support a role for COPI in the retrieval of membrane proteins that expose an Arg-based signal (26) . Rennolds et al. (32) recently reported the presence of several Arg-reach motifs in CFTR, which mediated retrograde transport to the endoplasmic reticulum (ER) of the mutant CFTR, but these motifs were also necessary for COPIassisted anterograde transport of wild-type CFTR. In distinction to COOH-terminal K(X)KXX ER-retention signal, Argbased signals are present mostly inside of the cytoplasmic domains, often in the vicinity of the lipid bilayer. Here, we identified one such sequence in the linker region of the P-gp (see Fig. 7 ). To verify the importance of the IRKR signal, we tested the effect of its mutation on P-gp processing and conclude that it is important for P-gp maturation. Immunoprecipitation experiments also indicate that P-gp interacts with COP-␣, one of the COPI subunits, and that this interaction is influenced by the hIRIP level (Fig. 8) . Involvement of the COPI complex in P-gp trafficking was also supported by the effects of the dominant-negative proteins, known to affect COPI dynamics on the P-gp function. We are currently investigating the COPI subunits that directly interact with the Arg-based signal.
Arg-based ER sorting motifs are thought to play an important role in assembly of the heteromultimeric proteins. The major mechanism of their function was established for several membrane proteins, and it mediates retention or retrieval in ER improperly assembled subunits when the signal is not masked by heteromultimeric assembly (26) . Despite some early data suggesting that P-glycoprotein can exist as a homodimer (2, 29, 35) , recent data indicate that it is present in the cells as a monomer. Two-dimensional crystals of the protein are monomeric (33) , and coprecipitation studies suggest that the protein functions as a monomer in HEK-293 cells (23, 37) . Therefore, Arg-based signals in P-glycoprotein, which we were able to identify most likely have role other than assisting the heteromultimeric protein assembly. Manipulation of the Arg-based signals in CFTR led to the profound effect on the ER quality control of CFTR mutant, present in 90% of cystic fibrosis patients (3). Thus, Arg-based signals can function to couple the folding state of the protein and translocation between intermediate transport compartments. At this stage, it is not known how or at which step this complex process is influenced by the hIRIP function. Possibilities include the participation of the protein in a folding process or in the mechanism of the certain structure recognition/cargo assembly and function. Interestingly, one the members of the SUA5/YrdC/YciO protein family, HypF from photosynthetic bacterium Rhodobacter capsulates, is involved in the maturation of the membrane-bound (NiFe) hydrogenase subunits (6) , although this protein is significantly larger and contains at least three additional domains: acylphosphatase, carbamoyltransferase, and zinc-finger containing domains.
Data presented correlate with another property of hIRIP we discovered earlier (13) , that is, the ability to bind to the RS1, regulator of the transporter's activity, which can influence dynamin-dependent trafficking at the trans-Golgi network of intracellular vesicles containing hSGLT1 and protein kinase C-dependent regulation of the transporter activity (19, 41, 42) . SUA5/YrdC/YciO domain proteins are ubiquitously distributed in prokaryotes and eukaryotes. Despite attempts to characterize the function of prokaryotic and yeast homologues of the hIRIP, their exact manner of action is also unknown (1, 38) . Several mechanisms have been proposed primarily on the basis of analysis of the three-dimensional structure of the other members of the family: YciO and YrdC proteins from Escherichia coli (12, 38) and SUA5 from the thermoacidophilic archaeon Sulfolobus tokodaii (1) . It has been reported that YrdC from E. coli binds preferentially to double-stranded RNA, although with relatively low affinity (38) . This protein was also characterized by genetic analysis of the suppressor mutations of the mutant allele of the ribosomal release factor and its role in the ribosome biogenesis was proposed (14) . On the basis of the three-dimensional structure of Sulfolobus, SUA5, and demonstration of ATP hydrolytic activity, Agari et al. (1) , suggested its involvement in nucleotide binding or metabolism (1) . None of these activities so far directly relate to the ability of the hIRIP to affect transporters activity, although indirect effect on proteins regulating transporter maturation and intracellular trafficking cannot be excluded. Because of the ability of hIRIP expression to respond to stress stimuli such as ischemia-reperfusion and septic shock (13), the protein can be a part of the adaptive response affecting maturation of certain classes of the transporters. This may have substantial effect on the adsorption/excretion of certain drugs and toxic compounds at physiological conditions. ABC transporters, including P-gp, mediate one of the most common mechanisms of the multidrug resistance (36) . In addition, experiments using knockout mice provided evidence for the important role of these transporters in the adsorption, excretion, and distribution of a variety of biologically active substances across the cell membrane. Recently, ABC transporters also have emerged as active participants in regulation of proliferation and differentiation of stem cells (21) . Several generations of P-glycoprotein inhibitors have been developed over the past decade to combat multidrug resistance of cancer (36) . Unfortunately, results of concomitant use of these inhibitors and anticancer drugs in cancer patients were disappointing. New inhibitors with different mechanisms of action are under development or in clinical trials, and it remains to be seen how effective they are. Search for additional modulators of these transporters warrants further studies on the mechanism of IRIP action and may provide new approaches for combating multidrug-resistant cancer.
